Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
  • inderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

Analyst Group: Analyst Group Comment on STENOCARE’s Q3-report 2025

Stenocare

STENOCARE A/S (STENOCARE or the “Company”) published on October 22nd the Company’s Q3-report for 2025.

The following are some key points that we have chosen to highlight in connection with the report:

  • The growth trend continued – net sales increased 11% Q-Q
  • Astrum 10-10 oil is being prescribed to patients in Germany
  • Reaches positive EBITDA for the second consecutive quarter
  • Positive operating cash flow

In conclusion, Analyst Group views STENOCARE’s Q3-25 report as another confirmation of the Company’s operational momentum and successful execution of the STENOCARE 3.0 strategy. The continued growth in Denmark demonstrates sustained market demand and recovery following previous market challenges. Meanwhile, Astrum oil, launched across three international markets, is expected to become an increasingly important growth driver in 2026 as market adoption advances. Moreover, the second consecutive quarter of positive EBITDA and operating cash flow highlights the improved cost structure and scalability of the business model. With expanding international presence and a differentiated product portfolio, STENOCARE is well positioned for continued profitable growth going forward.


Read Analyst Group’s comment on the report here


About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Stenocare. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.